Cascade of care for hepatitis C virus infection within the US veterans health administration

American Journal of Public Health

Volumn 106, Issue 2, 2016, Pages 353-358

  Maier, Marissa M ^a,b   Ross, David B ^c   Chartier, Maggie ^b,d   Belperio, Pamela S ^e,f   Backus, Lisa I ^f,g  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b VA Headquarters   (United States)

^c VHA   (United States)

^d SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^f VHA   (United States)

^g VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

GENOTYPE; GOVERNMENT; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMAN; ISOLATION AND PURIFICATION; MIDDLE AGED; PREVALENCE; REGISTER; UNITED STATES; VETERAN;

ANTIVIRAL AGENTS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MIDDLE AGED; PREVALENCE; REGISTRIES; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS; VETERANS;

EID: 84955609832     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2015.302927     Document Type: Article

References (18)

1. Denniston MM, Jiles RB, Drobeniuc J, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003-2010. Ann Intern Med. 2014;160(5):293-300.
2. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1992 through 2002. Ann Intern Med. 2006;144(10):705-714.
3. Backus LI, Belperio PS, Loomis TP,Yip GH, Mole LA. Hepatitis C virus screening and prevalence among US veterans in Department of Veterans Affairs care. JAMA Intern Med. 2013;173(16):1549-1552.
4. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975-982.
5. Manns MP, McHutchinson JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet. 2001;358 (9286):958-965.
6. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483-1493.
7. Afdhal N, Zuezem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889-1898.
8. Dieperink E, Pocha C, Thuras P, Knott A, Colton S, Ho SB. All-cause mortality and liver-related outcomes following successful antiviral treatment for chronic hepatitis C. Dig Dis Sci. 2014;59(4):872-880.
9. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011;9(6):509.e1-516.e1.
10. Morgan TR, Ghany MG, Kim H, Snow KK, Shiffman ML, De Santo JL. Outcome of sustained virological responders with histologically advanced hepatitis C. Hepatology. 2010;52(3):833-844.
11. Yehia BR, Schranz AJ, Umscheid CA, Lo RV. The treatment cascade for chronic hepatitisCvirus infection in the United States: A systematic review and meta-analysis. PLoS One. 2014;9(7):e101554.
12. Backus LI, Belperio PS, Loomis TP, Mole LA. Impact of race/ethnicity and gender on HCV screening and prevalence amongUS veterans in Department of Veterans Affairs care. Am J Public Health. 2014;104(suppl 4): S555-S561.
13. Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born 1945-1965. MMWR Recomm Rep. 2012;61(RR-4):1-32.
14. Backus LI, Gavrilov S, Loomis TP, et al. Clinical case registries: simultaneous local and national disease registries for population quality management. J Am Med Inform Assoc. 2009;16(6):775-783.
15. International Classification of Diseases, Ninth Revision. Geneva, Switzerland: World Health Organization; 1980.
16. Spradling PR, Rupp L, Moorman AC, et al. Hepatitis B and C virus infection among 1.2 million persons with access to care: factors associated with testing and infection prevalence. Clin Infect Dis. 2012;55(8):1047-1055.
17. Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N Engl J Med. 2013;368(20):1859-1861.
18. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep. 1998;47(RR-19):1-39.